Credit Suisse: Maintaining the Mineralys Therapeutics (MLYS.US) rating, adjusted from superior to market ratings, the target price was adjusted from $38.00 to $37.00.
瑞信：维持Mineralys Therapeutics(MLYS.US)评级，由优于大市调整至优于大市评级, 目标价由38.00美元调整至37.00美元。
Credit Suisse: Maintaining the Mineralys Therapeutics (MLYS.US) rating, adjusted from superior to market ratings, the target price was adjusted from $38.00 to $37.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.